logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Leukemia Myelogenous Chronic Bcrabl Positive

    FiltersReset Filters
    16 results

    • bosulif

      (Bosutinib)
      U.S. Pharmaceuticals
      Usage: BOSULIF is indicated for treating adults and pediatric patients (1 year and older) with chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), as well as adults with accelerated or blast phase Ph+ CML who are resistant or intolerant to prior therapies.

    • busulfan

      (Busulfan)
      Amneal Pharmaceuticals LLC
      Usage: Busulfan injection is indicated in combination with cyclophosphamide as a conditioning regimen before allogeneic hematopoietic progenitor cell transplantation in patients with chronic myelogenous leukemia.

    • busulfan

      (Busulfan)
      Eugia US LLC
      Usage: Busulfan injection is indicated for use alongside cyclophosphamide as a conditioning regimen before allogeneic hematopoietic progenitor cell transplantation in patients with chronic myelogenous leukemia.

    • cyclophosphamide

      (cyclophosphamide)
      Dr. Reddy's Laboratories Inc.
      Usage: Cyclophosphamide is indicated for treating malignant diseases in adults and pediatric patients, including various lymphomas, multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of the ovary, retinoblastoma, and breast carcinoma. It is often used in combination with other antineoplastic agents.

    • cytarabine

      (CYTARABINE)
      Fresenius Kabi USA, LLC
      Usage: Cytarabine Injection is indicated for remission induction in acute non-lymphocytic leukemia in adults and pediatric patients, and for treating acute non-lymphocytic leukemia and blast phase chronic myelocytic leukemia. It is also used intrathecally for prophylaxis and treatment of meningeal leukemia.

    • cytarabine

      (Cytarabine)
      Meitheal Pharmaceuticals Inc.
      Usage: Cytarabine Injection, in combination with other anti-cancer drugs, is indicated for remission induction in acute non-lymphocytic leukemia, acute lymphocytic leukemia, and the blast phase of chronic myelocytic leukemia. It is also used intrathecally for prophylaxis and treatment of meningeal leukemia.

    • dasatinib

      (Dasatinib)
      Dr. Reddy's Laboratories Inc.
      Usage: Dasatinib tablets are indicated for adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and those with advanced Ph+ CML or Ph+ acute lymphoblastic leukemia (ALL) who are resistant or intolerant to prior therapy. They are also approved for pediatric patients with Ph+ CML and newly diagnosed Ph+ ALL.

    • dasatinib

      (dasatinib)
      Biocon Pharma Inc.
      Usage: Dasatinib is indicated for treating adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase, Ph+ CML with resistance to prior therapy, and Ph+ acute lymphoblastic leukemia (ALL). It is also indicated for pediatric patients aged 1 and older with Ph+ CML and newly diagnosed Ph+ ALL.

    • dasatinib

      (Dasatinib)
      Apotex Corp.
      Usage: Dasatinib tablets are indicated for adults with newly diagnosed Ph+ chronic myeloid leukemia (CML) in chronic phase, resistant or intolerant Ph+ CML, and Ph+ acute lymphoblastic leukemia (ALL). It is also for pediatric patients (1 year and older) with Ph+ CML and newly diagnosed Ph+ ALL with chemotherapy.

    • dasatinib

      (dasatinib)
      Prasco Laboratories
      Usage: Dasatinib tablets are indicated for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML), Ph+ CML with resistance/intolerance to prior therapy, and Ph+ acute lymphoblastic leukemia (ALL). They are also indicated for pediatric patients (≥1 year) with Ph+ CML and newly diagnosed Ph+ ALL with chemotherapy.